Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636256 · ClinicalTrials.gov registry record · Phase 1
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
A Phase 1 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03636256 is a Phase 1 study that has completed, run by NanOlogy. The registered enrollment target is 36 participants.
The verdict
NCT03636256, a Phase 1 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma.
Interventions
- DRUG NanoDoce (direct injection)
- DRUG NanoDoce (intravesical instillation) - Visit 2 Instillation
- OTHER Institutional Standard of Care
- DRUG NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636256
The ClinicalTrials.gov registry entry for NCT03636256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NanoDoce (direct injection) is the first listed.
NCT03636256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636256 about?
NCT03636256 is a clinical study titled "Evaluation of NanoDoce® in Participants With Urothelial Carcinoma". This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effect...
What is the current status of trial NCT03636256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-04-02. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT03636256?
The interventions under investigation include: NanoDoce (direct injection) (DRUG), NanoDoce (intravesical instillation) - Visit 2 Instillation (DRUG), Institutional Standard of Care (OTHER), NanoDoce (intravesical instillation) - Induction and Maintenance Instillations (DRUG).
Who is sponsoring clinical trial NCT03636256?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.